

Is There a Role of Early Neonatal Events in Susceptibility to Allergy?

F. Gloria-Bottini, E. Bottini

Division of Human Population Biopathology and Environmental Pathology, Department of Biopathology and Imaging Diagnostics, University of Rome "Tor Vergata", School of Medicine, Rome, Italy

ABSTRACT

Background: Several studies suggest a protective role of bilirubin against oxidative damage during the neonatal period. ADA₁*2 allele has been found associated with higher bilirubin levels in newborns and with a protective action against bronchial asthma. Thus the relation between ADA₁ and asthma could be mediated by events occurring during the early extrauterine life. Moreover the increased prevalence of allergic diseases in western populations parallels the widespread practice of phototherapy during the neonatal period. These observations prompted us to reevaluate our previous data and show new observations. **Methods:** Data from 2729 previously studied subjects, from 53 subjects studied at birth and after 30 years and from a survey of phototherapy frequency in four Italian Hospital including 7392 newborns are reported. **Results:** ADA₁*2 allele carriers are less represented among asthmatic subjects than in controls ($p=0.0004$). ADA₁*2 allele carriers among newborns undergoing phototherapy for hyperbilirubinemia is higher when compared to newborns not undergoing this treatment ($p=0.006$). In infants treated by phototherapy, the maximum bilirubin level attained during the first few days of life positively correlated with the ADA₁*2 allele dose ($p=0.001$). Among subjects studied at birth, allergic rhinitis and/or conjunctivitis are more frequent among those treated with phototherapy than among those not treated ($p=0.046$). **Conclusions:** These observations support our hypothesis that ADA₁*2 allele through an increase of bilirubin level in the neonatal period protects infants from oxidative stress and favours Th₂→Th₁ switching thus preventing allergic manifestations in later periods of life. (*Int J Biomed Sci* 2010; 6(1):8-12)

Keywords: ADA₁; bilirubin; allergy

INTRODUCTION

Over the past four decades an increased prevalence of allergic diseases has been observed in most devel-

oped countries. Several causes have been proposed to explain this phenomenon. It has been suggested that decreased incidence and severity of early childhood infectious could have negatively influenced the expression of T-helper 1 (Th₁) subpopulation of cells resulting in a prevalence of the Th₂ subpopulation (1, 2). An important role has been attributed to the worsening environmental pollution. A decreased intake of dietary antioxidant substances could have also contributed to the rise in this class of diseases (2).

Genetic factors controlling early neonatal events could influence the switch from Th₂ to Th₁ subpopulations. This aspect has not received much attention.

Corresponding author: Fulvia Gloria-Bottini, Department of Biopathology and Imaging Diagnostics, University of Rome Tor Vergata, Via Montpellier 1, 00233 Rome, Italy. Tel: +39-06-72596030; Fax: +39-06-72596028; E-mail: gloria@med.uniroma2.it.

Received July 27, 2009; **Accepted** October 10, 2009

Copyright: © 2010 Fulvia Gloria-Bottini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.5/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

It is well known that in the first few days of extrauterine life there is a physiologic rise of serum bilirubin due to a transitory increase of red blood cells destruction and to a deficiency of mechanisms involved in the bilirubin elimination. Since elevated levels of serum bilirubin may induce severe damages to the central nervous system, in the past four decades, phototherapy has been a widely used procedure to lower serum bilirubin levels in the newborn.

More recent studies (3, 4, 5) indicate a beneficial effect of bilirubin in the neonatal period as a result of its protective effects from secondary oxidants formed in the oxidative process although some observations suggest an interaction of other factors (6). Since the newborn is particularly susceptible to oxidative damage, bilirubin could have an important role in the regulation of neonatal events involved in the switch from Th₂ to Th₁ subpopulations.

Previous studies by our group have shown an association of Adenosine Deaminase locus 1 (ADA₁) polymorphisms with allergic manifestations in children and adults (7, 8) and with bilirubin levels in the newborn [(9, 10). This suggests that the effects of ADA on susceptibility to allergy could be correlated with the effects of ADA on bilirubin levels.

We present (i) an update of our previous observations and (ii) new observations on a small sample of subjects studied at birth and after thirty years. We also show (iii) a survey of the frequency of phototherapy in several hospitals.

Adenosine Deaminase genetic polymorphism

Adenosine deaminase (ADA) is a polymorphic enzyme present in all mammalian tissues (11). ADA is located on the long arm of chromosome 20. The ADA₁ site controls ADA activity. Two codominant alleles, ADA₁*1 and ADA₁*2 are present and are associated with different enzymatic activity. The corresponding three common ADA₁ phenotypes (12) have different degrees of enzymatic activity. ADA₁1 is 15% more active than ADA₁ 2/1 and 30% more active than ADA₁ 2 (13).

The ADA tissue enzymes consist of one or more molecules of RBC ADA and one molecule of adenosine deaminase complexing protein (ADPC) (14).

ADPC is identical with CD26 (a T-cell activator molecule). ADA expression may be connected with T-cell activation (15, 16).

ADA catalyses the irreversible deamination of adenosine to inosine. In purine metabolism, the classical function of the ADA enzyme is considered to be the regulation of intra-and extracellular levels of adenosine. ADA is present on the surface of many cell types, including lymphocytes where it acts as an ectoenzyme (17). A co-stimulatory role has been observed for ADA bound with CD26 on lymphocyte surface with adenosine 1 receptors (A1R).

Current interest is focused on the effects produced by adenosine activation via surface adenosine receptors. Four adenosine receptors (A1, A2a, A2b and A3) exist on the surface of different cell types (18). In the respiratory system, the bronco-constrictor effects of adenosine are well known (19). Thus, ADA₁ polymorphism could modulate adenosine receptor activity in the respiratory tract via the signal transduction pathway of adenosine and other mediators.

Mice studies have shown a relationship between ADA and an inflammatory phenotype in the lungs, similar to human asthma. This includes extensive mast cell degranulation, eosinophilia, activation of alveolar macrophages, increase in baseline airway resistance and AHR (20-23).

Some observations suggest that ADA activity may influence the expression of Th cytokine genes (24).

MATERIALS AND METHODS

Subjects

We have reconsidered the following group samples:

291 asthmatic children (sample 1) and 1417 control-children (sample 2) from the Italian population (7) (Table 1).

Table 1. Distribution of ADA₁ phenotypes in asthmatic patients and in controls

| | Carriers of ADA ₁ *2 allele (% proportion) | Total (n°) | Chi square test of independence | ODDS Ratio |
|---------------------------|---|------------|---------------------------------|----------------------------------|
| ITALIAN POPULATION | | | | |
| Asthmatic children | 11.4% | 291 | p=0.02 | O.R. =0.637 95%C.I. 0.42-0.95 |
| Control children | 16.7% | 1417 | | |
| CHINESE POPULATION | | | | |
| Asthmatic adults | 10.0% | 120 | p=0.002 | O.R.=0.318 95%C.I. 0.14-0.69 |
| Control adults | 25.9% | 116 | | |

Cumulative Chi square test of independence of ADA₁*2 allele and asthma p=0.0004.

120 asthmatic adults (sample 3) and 116 control adults (sample 4) from the Chinese Han population (8) (Table 1).

785 consecutive newborns from the Italian population (9, 10) (sample 5) (Table 2).

We performed a retrospective survey interviewing previously identified cohort studied at birth more than 30 years ago. Out of 400 subjects studied at birth only 53 were still living at the address given on clinical records. We asked these 53 if they had allergic disorders including asthma, rhinitis and conjunctivitis. All subjects with allergic manifestations reported that they had at least one positive prick test (sample 6) (Table 4).

Table 2. Proportion % of carriers of the ADA₁*2 allele among newborns treated with phototherapy for hyperbilirubinemia and among newborns not treated

| | Proportion % of ADA ₁ *2 allele carriers | Total (n°) |
|--------------------------------------|---|------------|
| Newborns treated by phototherapy | 23.6% | 123 |
| Newborns not treated by phototherapy | 13.7% | 662 |
| Chi square test of independence | p=0.006 | |
| ODDS Ratio | 1.933 95%C.I. 1.741-3.178 | |

Table 3. Mean values of maximum bilirubin levels (mg/dl) attained during the first few days of life in newborns treated by phototherapy in relation to ADA₁ phenotype

| | ADA ₁ | ADA ₂ -1 | ADA ₂ |
|------------------------------|------------------|---------------------|------------------|
| Mean bilirubin level (mg/dl) | 11.8 | 13.6 | 15.3 |
| S.E. | 0.3 | 0.4 | - |
| N° | 34 | 11 | 1 |
| Variance analysis | P=0.004 | | |
| Linear correlation | P=0.001 | | |
| Eta squared | 0.23 | | |

Table 5. Proportion (percent) of newborns treated with phototherapy in relation to locality and gender

| | Locality | | | | | | | |
|--|----------|---------|-------|---------|------------------|---------|------------------|---------|
| | Sassari | | Penne | | Roma La Sapienza | | Roma Tor Vergata | |
| | Males | Females | Males | Females | Males | Females | Males | Females |
| Proportion (%) of newborns treated by phototherapy | 22.1% | 18.7% | 33.7% | 24.5% | 12.0% | 13.1% | 7.6% | 4.9% |
| N° | 2860 | 2680 | 184 | 204 | 175 | 206 | 576 | 507 |
| Three way contingency table analysis by a log-linear model (x=sex; y=phototherapy; z=locality) | | | | | | | | |
| Interaction xyz | p=N.S. | | | | | | | |
| Association xy | p<0.005 | | | | | | | |
| Association yz | p<<0.001 | | | | | | | |

We have carried out a survey in four Italian Hospitals in order to evaluate the proportion of newborns undergoing phototherapy in the neonatal period.

5540 newborns from Sassari (Sardinia) (sample 7), 388 from Penne (Continental Italy) (sample 8), 381 from the University of Rome La Sapienza (sample 9) and 1083 from the University of Rome Tor Vergata (sample 10) were considered (Table 5).

Methods

ADA₁ phenotype was determined by starch gel electrophoresis (12) in sample groups 1, 2 and 5. In sample groups 3 and 4, ADA₁ genotype was determined by DNA analysis (8). We have shown no difference between starch gel electrophoresis and DNA analysis.

Chi square test of independence was performed by SPSS programs (25). Three way contingency table analysis was carried out according to Sokal and Rohlf (26).

RESULTS

Table 1 shows the distribution of ADA₁ phenotypes in asthmatic patients and in controls. In both Italian and Chi-

Table 4. Phototherapy in the neonatal period and development of allergic manifestations later in life

| | Subjects not treated by phototherapy | Subjects treated by phototherapy |
|------------------------------------|--------------------------------------|----------------------------------|
| No allergic manifestations (a) | 39 | 2 |
| Asthma (b) | 5 | 0 |
| Rhinitis and/or conjunctivitis (c) | 7 | 3 |
| Test of independence | p | |
| a vs b vs c | 0.034 | |
| a vs b | N.S. | |
| a vs c | 0.046 | |

nese populations a significant associations between asthma and ADA₁*2 allele (genotype) is observed. Carriers of ADA₁*2 allele are less represented among asthmatics versus controls suggesting a protective role of this allele against asthmatic phenotypes.

Table 2 shows the proportion of carriers of ADA₁*2 allele among newborns treated with phototherapy for hyperbilirubinemia and among newborns not treated. The proportion of subjects carrying the ADA₁*2 allele is significantly higher in newborn treated with phototherapy versus untreated newborns. This indicates that ADA₁*2 allele is positively associated with higher bilirubin levels in the neonatal period.

Table 3 shows the maximum bilirubin level attained in the first few days of life in newborns treated with phototherapy. These newborns were a subsample of sample 5 in which the bilirubin level was registered in all infants during the first five days of life. A highly significant positive association is observed between a maximum bilirubin level and ADA₁*2 allele dose.

Table 4 shows the absolute frequencies of allergic manifestations in relation to treatment with phototherapy during the neonatal period (sample 6). Rhinitis and conjunctivitis were manifest during childhood. Among subjects with asthma, only two subjects referred to have had this manifestation during childhood. A significant positive association is observed between phototherapy and allergic rhinitis and/or conjunctivitis.

Table 5 shows the proportion of newborns treated by phototherapy in relation to locality and gender. There is a strong heterogeneity among Hospitals reflecting the different criteria adopted to treat the newborn with phototherapy. The proportion of newborns treated reached a maximum in males from Penne (33.7%) and a minimum in females from Rome Tor Vergata (4.9%). In general the frequency of phototherapy was lower in females.

DISCUSSION

The data shown in Tables 1 and 2 show a negative correlation between ADA₁*2 allele and asthma and a positive correlation between ADA₁*2 allele and bilirubin levels in the neonatal period. Parallel to these correlations are two epidemiological data: the widespread practice of phototherapy in the neonatal period and the rise of asthma and other allergic manifestations in Western populations. Preliminary data reported in Table 4 suggest a positive relationship between phototherapy and allergy.

Because of the protective role of bilirubin from oxidative damage during the neonatal period, we speculate that the relationship between ADA₁*2 allele and asthma is mediated in part by the relationship between ADA₁*2 and bilirubin level in the newborn. Our data support the hypothesis that ADA₁*2 favouring high level of bilirubin has a beneficial effect on oxidative damage and in turn protects from allergic manifestations later in life.

Substances that contribute to antioxidant defence protect from asthma (2): it is possible that oxidative damage of respiratory tract in the neonatal period may represent a predisposing factor to asthmatic manifestations later in life.

The role of oxidative stress on the switch Th₂→Th₁ subpopulations during the neonatal period has not been fully studied. Increasing bilirubin level ADA₁*2 allele could decrease oxidative stress favouring Th₂→Th₁ switch thus explaining the negative correlation between ADA₁*2 and asthma.

The positive relationship between phototherapy and allergy observed in the small sample of subjects studied at birth and after 30 years supports our hypothesis: The decrease of bilirubin level induced by phototherapy favours the oxidative stress resulting in an increased susceptibility to allergy. However, the possibility of a direct negative effect of light on oxidative stress and on Th₂→Th₁ switch cannot be excluded.

The long term iatrogenic consequences of phototherapy in the population are not yet known. An epidemiological study on a larger sample of subjects examined at birth and after few decades is needed.

REFERENCES

1. Maziak W. Asthma and farming. *The Lancet*. 2002; 359: 623.
2. Greene LS. Asthma, oxidant stress, and diet. *Nutrition*. 1999 Nov-Dec; 15 (11-12): 899-907.
3. Bélanger S, Lavoie JC, Chessex P. Influence of bilirubin on the antioxidant capacity of plasma in newborn infants. *Biol. Neonate*. 1997; 71: 233-238.
4. Dailly E, Urien S, Barré J, Reinert P, *et al*. Role of bilirubin in the regulation of the total peroxy radical trapping antioxidant activity of plasma in sickle cell disease. *Biochem. Biophys. Res. Commun*. 1998; 248: 303-306.
5. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. *Arch. Biochem. Biophys*. 1998; 352: 165-174.
6. Dani C, Masini E, Bertini G, di Felice AM, *et al*. Role of heme oxygenase and bilirubin in oxidative stress in preterm infants. *Pediatr. Res*. 2004; 56: 873-878.
7. Ronchetti R, Lucarini N, Lucarelli P, Martinez F, *et al*. A genetic basis for heterogeneity of asthma syndrome in pediatric ages: adenosine deaminase phenotypes. *J. Allergy. Clin. Immunol*. 1984; 74: 81-84.

8. Liu Y, Saccucci P, Qi H, Wu HC, *et al.* ADA polymorphism and asthma: A study in the Chinese Han population. *Journal of Asthma.* 2006; 43: 203-206.
9. Lepore A, Lucarini N, Evangelista MA, Palombaro G, *et al.* Enzyme variability and neonatal jaundice. The role of adenosine deaminase and acid phosphatase. *J. Perinat. Med.* 1989; 17: 195-201.
10. Gloria-Bottini F, Magrini A, Cozzoli E, Bergamaschi A, *et al.* ADA genetic polymorphism and the effect of smoking on neonatal bilirubinemia and developmental parameters. *Early Hum. Dev.* 2008; 84: 739-743.
11. Edwards YH, Hopkinson DA, Harris H. Adenosine deaminase isozymes in human tissues. *Ann. Hum. Genet.* 1971 Oct; 35 (2): 207-219. No abstract available.
12. Spencer N, Hopkinson D, Harris H. Adenosine deaminase polymorphism in man. *Ann. Hum. Genet.* 1968; 32: 9-14.
13. Battistuzzi C, Scozzari R, Santolamazza P, Terrenato L, *et al.* Comparative activity of red cell adenosine deaminase allelic form. *Nature.* 1974; 251: 712.
14. MacKusic VA. Mendelian inheritance in man. *Baltimore, MD: The Johns Hopkins University Press.* 1994.
15. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, *et al.* Direct association of adenosine deaminase with a T cell activation antigen, CD26. *Science.* 1993; 261: 466-469.
16. Dong RP, Kameoka J, Hegen M, Tanaka T, *et al.* Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. *J. Immunol.* 1996; 156: 1349-1355.
17. Franco R, Valenzuela A, Lluís C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. *Immunol. Rev.* 1998; 161: 27-42.
18. Dalziel HH, Westfall DP. Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization. *Pharmacol. Rev.* 1994; 46: 449-466.
19. Polosa R, Holgate ST. Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? *Thorax.* 1997; 52: 919-923.
20. Blackburn MR, Aldrich M, Volmer JB, Chen W, *et al.* The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. *J. Biol. Chem.* 2000; 275: 32114-32121.
21. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, *et al.* Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. *J. Exp. Med.* 2000; 192: 159-170.
22. Zhong H, Chunn JL, Volmer JB, Fozard JR, *et al.* Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. *J. Pharmacol. Exp. Theor.* 2001; 298: 433-440.
23. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, *et al.* Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. *J. Immunol.* 2001; 167: 4676-4685.
24. Kawamura N, Ariga T, Ohtsu M, Yamada M, *et al.* Elevation of serum IgE level and peripheral eosinophil count during T lymphocyte-directed gene therapy for ADA deficiency: implication of Tc2-like cells after gene transduction procedure. *Immunol. Lett.* 1998; 64: 49-53.
25. SPSS/PC Version 5.0 SPSS Inc, Chicago. 1992.
26. Sokal RR, Rohlf FJ. *Biometry.* New York, NY: *Freeman.* 1981.